title: Myeloma and second primary cancers.
authors.forename: Ola
authors.initials: O
authors.lastname: Landgren
authors.forename: Anish
authors.initials: A
authors.lastname: Thomas
authors.forename: Sham
authors.initials: S
authors.lastname: Mailankody
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D006801:Humans; D000077269:Lenalidomide; D007951:Leukemia, Myeloid / Q000209:etiology; D008558:Melphalan / Q000008:administration & dosage / Q000009:adverse effects; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy; D009190:Myelodysplastic Syndromes / Q000209:etiology; D016609:Neoplasms, Second Primary / Q000209:etiology*; D011336:Probability; D018570:Risk Assessment; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide; D008558:Melphalan